Xopenex levalbuterol: Phase III; marketed to treat asthma in patients 12 and older who use nebulizers

Thomas Jefferson University researchers published in the Journal of Allergy and Clinical Immunology data from 28 patients in a cross-over study showing that 0.31 mg levalbuterol produced similar effic...